Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...
More »SEARCH RESULT
Total Matching Records found : 520
Now help for domestic help
-The Hindustan Times In April, after yet another story of maid abuse came out in the open, a news magazine ran a cover story titled, ‘The new slaves’. While many would cringe at the thought of equating domestic workers with slaves, unfortunately that is exactly how many families treat their domestic help, taking advantage of a crowded labour market, lack of a credible support system for the help, weak implementation of...
More »The government needs to think out of the box to help pharma grow while keeping medicines affordable-Ramesh Adige
Having watched from the ringside for many years now, I have no doubt in advising that the steering wheel must be firmly grasped by the government and direction given to policies that should be stable for at least the medium term. This is crucial for the growth of Indian pharma, a $20-billion industry growing at an average of 12% considering both domestic and export arenas. Price control: The biggest and most...
More »Supreme Court should halt undermining of the purpose of setting up an SIT
-The Economic Times The Supreme Court-appointed Special Investigation Team (SIT) has concluded in its final report that it would not amount to an offence even if Gujarat chief ministerNarendra Modi hypothetically did say something about 'allowing Hindus to vent their anger' in a meeting with top police officers after the Godhra carnage in 2002. That is an appalling conclusion. If Modi did actually make that statement, it patently cannot be called...
More »Bayer to challenge Cipla’s decision to cut price of cancer drug
-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...
More »
